{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:18:32Z","timestamp":1793305112716,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fonds de la Recherche Scientifique \u2013 FNRS","award":["Charg\u00e9 de recherche"],"award-info":[{"award-number":["Charg\u00e9 de recherche"]}]},{"name":"Fonds de la Recherche Scientifique \u2013 FNRS","award":["Aspirant"],"award-info":[{"award-number":["Aspirant"]}]},{"name":"Fonds de la Recherche Scientifique \u2013 FNRS","award":["Aspirant"],"award-info":[{"award-number":["Aspirant"]}]},{"name":"Fonds de la Recherche Scientifique \u2013 FNRS","award":["Charg\u00e9 de recherche"],"award-info":[{"award-number":["Charg\u00e9 de recherche"]}]},{"name":"Fonds de la Recherche Scientifique \u2013 FNRS","award":["40021386 \u2013 PDR"],"award-info":[{"award-number":["40021386 \u2013 PDR"]}]},{"name":"Televie","award":["40012435"],"award-info":[{"award-number":["40012435"]}]},{"name":"Televie","award":["40007654"],"award-info":[{"award-number":["40007654"]}]},{"name":"WEL Research Institute","award":["FRFS-WELBIO-CR-2017S-01"],"award-info":[{"award-number":["FRFS-WELBIO-CR-2017S-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02454-z","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:02:28Z","timestamp":1762246948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["SHIP2\u2013PLK1 crosstalk promotes sensitivity to dual inhibition in esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Ana Raquel","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Bregni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Gillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunie","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Bodart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliz\u00e9e","family":"Vercauteren Drubbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louison","family":"Descampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Moresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bisteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Verheye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheleya","family":"Pirard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Erneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2454_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163:649\u2013e6582.","journal-title":"Gastroenterology"},{"key":"2454_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00419-3","volume":"18","author":"AP Thrift","year":"2021","unstructured":"Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2021;18:432\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2454_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495\u2013501.","journal-title":"Nature"},{"key":"2454_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605\u201335.","journal-title":"Cell"},{"key":"2454_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD. The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74\u201388.","journal-title":"Nat Rev Cancer"},{"key":"2454_CR6","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1002\/j.1460-2075.1996.tb01045.x","volume":"15","author":"DR Alessi","year":"1996","unstructured":"Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541\u201351.","journal-title":"EMBO J"},{"key":"2454_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0960-9822(06)00122-9","volume":"7","author":"DR Alessi","year":"1997","unstructured":"Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261\u20139.","journal-title":"Curr Biol"},{"key":"2454_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of akt\/pkb by the Rictor-mTOR complex. Science. 2005;307:1098\u2013101.","journal-title":"Science"},{"key":"2454_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/BST20150248","volume":"44","author":"PT Hawkins","year":"2016","unstructured":"Hawkins PT, Stephens LR. Emerging evidence of signalling roles for PI(3,4) P 2 in class I and II PI3K-regulated pathways. Biochem Soc Trans. 2016;44:307\u201314.","journal-title":"Biochem Soc Trans"},{"key":"2454_CR10","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1016\/j.molcel.2023.07.015","volume":"83","author":"TAM Chessa","year":"2023","unstructured":"Chessa TAM, Jung P, Anwar A, Suire S, Anderson KE, Barneda D, et al. PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate. Mol Cell. 2023;83:2991\u2013e300913.","journal-title":"Mol Cell"},{"key":"2454_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.molcel.2016.12.028","volume":"65","author":"M Ebner","year":"2017","unstructured":"Ebner M, Lu\u010di\u0107 I, Leonard TA, Yudushkin I. PI(3,4,5)P3 engagement restricts Akt activity to cellular membranes. Mol Cell. 2017;65:416-e4316.","journal-title":"Mol Cell"},{"key":"2454_CR12","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","volume":"30","author":"SE Nunnery","year":"2019","unstructured":"Nunnery SE, Mayer IA. Management of toxicity to isoform \u03b1-specific PI3K inhibitors. Ann Oncol. 2019;30:x21\u20136.","journal-title":"Ann Oncol"},{"key":"2454_CR13","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1083\/jcb.201809026","volume":"218","author":"BD Goulden","year":"2019","unstructured":"Goulden BD, Pacheco J, Dull A, Zewe JP, Deiters A, Hammond GRV. A high-avidity biosensor reveals plasma membrane PI(3,4)P2 is predominantly a class I PI3K signaling product. J Cell Biol. 2019;218:1066\u201379.","journal-title":"J Cell Biol"},{"key":"2454_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1152\/physrev.00028.2012","volume":"93","author":"T Balla","year":"2013","unstructured":"Balla T. Phosphoinositides. Tiny lipids with giant impact on cell regulation. Physiol Rev. 2013;93:1019\u2013137.","journal-title":"Physiol Rev"},{"key":"2454_CR15","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/bies.201100195","volume":"34","author":"WE Edimo","year":"2012","unstructured":"Edimo WE, Janssens V, Waelkens E, Erneux C. Reversible ser\/thr SHIP phosphorylation: a new paradigm in phosphoinositide signalling? Targeting of SHIP1\/2 phosphatases may be controlled by phosphorylation on Ser and Thr residues. Bioessays. 2012;34:634\u201342.","journal-title":"Bioessays"},{"key":"2454_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1042\/BST20150214","volume":"44","author":"MJ Eramo","year":"2016","unstructured":"Eramo MJ, Mitchell CA. Regulation of PtdIns(3,4,5)P3\/Akt signalling by inositol polyphosphate 5-phosphatases. Biochem Soc Trans. 2016;44:240\u201352.","journal-title":"Biochem Soc Trans"},{"key":"2454_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00424-007-0304-5","volume":"455","author":"D Blero","year":"2007","unstructured":"Blero D, Payrastre B, Schurmans S, Erneux C. Phosphoinositide phosphatases in a network of signalling reactions. Pflugers Arch - Eur J Physiol. 2007;455:31\u201344.","journal-title":"Pflugers Arch - Eur J Physiol"},{"key":"2454_CR18","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.2174\/1381612822666160226132512","volume":"22","author":"C Erneux","year":"2016","unstructured":"Erneux C, Ghosh S, Raquel Ramos A, Elong Edimo W. New functions of the inositol polyphosphate 5-phosphatases in cancer. CPD. 2016;22:2309\u201314.","journal-title":"CPD"},{"key":"2454_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jbior.2017.09.001","volume":"67","author":"AR Ramos","year":"2018","unstructured":"Ramos AR, Elong Edimo W, Erneux C. Phosphoinositide 5-phosphatase activities control cell motility in glioblastoma: two phosphoinositides PI(4,5)P2 and PI(3,4)P2 are involved. Adv Biol Regul. 2018;67:40\u20138.","journal-title":"Adv Biol Regul"},{"key":"2454_CR20","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.216408","volume":"131","author":"S Ghosh","year":"2018","unstructured":"Ghosh S, Scozzaro S, Ramos AR, Delcambre S, Chevalier C, Krejci P, et al. Inhibition of SHIP2 activity inhibits cell migration and could prevent metastasis in breast cancer cells. J Cell Sci. 2018;131:jcs216408.","journal-title":"J Cell Sci"},{"key":"2454_CR21","doi-asserted-by":"publisher","first-page":"e2017645118","DOI":"10.1073\/pnas.2017645118","volume":"118","author":"Z Feng","year":"2021","unstructured":"Feng Z, Yu C. PI(3,4)P 2 -mediated membrane tubulation promotes integrin trafficking and invasive cell migration. Proc Natl Acad Sci USA. 2021;118:e2017645118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2454_CR22","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1021\/cr000091i","volume":"101","author":"NR Leslie","year":"2001","unstructured":"Leslie NR, Biondi RM, Alessi DR. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem Rev. 2001;101:2365\u201380.","journal-title":"Chem Rev"},{"key":"2454_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1006\/smim.2000.0222","volume":"12","author":"G Krystal","year":"2000","unstructured":"Krystal G. Lipid phosphatases in the immune system. Semin Immunol. 2000;12:397\u2013403.","journal-title":"Semin Immunol"},{"key":"2454_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0014-5793(98)01255-1","volume":"437","author":"X Pesesse","year":"1998","unstructured":"Pesesse X, Moreau C, Drayer AL, Woscholski R, Parker P, Erneux C. The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity. FEBS Lett. 1998;437:301\u20133.","journal-title":"FEBS Lett"},{"key":"2454_CR25","doi-asserted-by":"publisher","first-page":"28348","DOI":"10.1074\/jbc.M103537200","volume":"276","author":"X Pesesse","year":"2001","unstructured":"Pesesse X, Dewaste V, De Smedt F, Laffargue M, Giuriato S, Moreau C, et al. The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in EGF-stimulated COS-7 cells. J Biol Chem. 2001;276:28348\u201355.","journal-title":"J Biol Chem"},{"key":"2454_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nature12308","volume":"499","author":"Y Zheng","year":"2013","unstructured":"Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A, et al. Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature. 2013;499:166\u201371.","journal-title":"Nature"},{"key":"2454_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aap8608","volume":"11","author":"B Fafilek","year":"2018","unstructured":"Fafilek B, Balek L, Bosakova MK, Varecha M, Nita A, Gregor T, et al. The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases. Sci Signal. 2018;11:eaap8608.","journal-title":"Sci Signal"},{"key":"2454_CR28","doi-asserted-by":"publisher","first-page":"73525","DOI":"10.18632\/oncotarget.12321","volume":"7","author":"E Hoekstra","year":"2016","unstructured":"Hoekstra E, Das AM, Willemsen M, Swets M, Kuppen PJK, van der Woude CJ, et al. Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation. Oncotarget. 2016;7:73525\u201340.","journal-title":"Oncotarget"},{"key":"2454_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/carcin\/bgm213","volume":"29","author":"NK Prasad","year":"2008","unstructured":"Prasad NK, Tandon M, Badve S, Snyder PW, Nakshatri H. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis. 2008;29:25\u201334.","journal-title":"Carcinogenesis"},{"key":"2454_CR30","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/stem.1735","volume":"32","author":"C-H Fu","year":"2014","unstructured":"Fu C-H, Lin R-J, Yu J, Chang W-W, Liao G-S, Chang W-Y, et al. A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of jnk\/vimentin activation. Stem Cells. 2014;32:2048\u201360.","journal-title":"Stem Cells"},{"key":"2454_CR31","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.2147\/OTT.S223422","volume":"12","author":"J Zhou","year":"2019","unstructured":"Zhou J, Di M, Han H. Upregulation of SHIP2 participates in the development of breast cancer via promoting Wnt\/\u03b2-catenin signaling. Onco Targets Ther. 2019;12:7067\u201377.","journal-title":"Onco Targets Ther"},{"key":"2454_CR32","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/2211-5463.12967","volume":"10","author":"A Azzi","year":"2020","unstructured":"Azzi A. SHIP2 inhibition alters redox-induced PI3K\/AKT and MAP kinase pathways via PTEN over-activation in cervical cancer cells. FEBS Open Bio. 2020;10:2191\u2013205.","journal-title":"FEBS Open Bio"},{"key":"2454_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.arcmed.2011.10.012","volume":"42","author":"X Zhou","year":"2011","unstructured":"Zhou X, Liu Y, Tan G. Prognostic value of elevated SHIP2 expression in laryngeal squamous cell carcinoma. Arch Med Res. 2011;42:589\u201395.","journal-title":"Arch Med Res"},{"key":"2454_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109392","volume":"118","author":"T Tang","year":"2019","unstructured":"Tang T, Xiao Z-Y, Shan G, Lei H-B. Descending-SHIP2-mediated radiosensitivity enhancement through PI3K\/Akt signaling pathway in laryngeal squamous cell carcinoma. Biomed Pharmacother. 2019;118:109392.","journal-title":"Biomed Pharmacother"},{"key":"2454_CR35","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1091\/mbc.e11-11-0958","volume":"23","author":"K Kato","year":"2012","unstructured":"Kato K, Yazawa T, Taki K, Mori K, Wang S, Nishioka T, et al. The inositol 5-phosphatase SHIP2 is an effector of RhoA and is involved in cell polarity and migration. Mol Biol Cell. 2012;23:2593\u2013604.","journal-title":"Mol Biol Cell"},{"key":"2454_CR36","first-page":"2515","volume":"6","author":"M Fu","year":"2013","unstructured":"Fu M, Gu X, Ni H, Zhang W, Chang F, Gong L, et al. High expression of inositol polyphosphate phosphatase-like 1 associates with unfavorable survival in hepatocellular carcinoma. Int J Clin Exp Pathol. 2013;6:2515\u201322.","journal-title":"Int J Clin Exp Pathol"},{"key":"2454_CR37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00535-015-1101-0","volume":"51","author":"Y Ye","year":"2016","unstructured":"Ye Y, Ge YM, Xiao MM, Guo LM, Li Q, Hao JQ, et al. Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt. J Gastroenterol. 2016;51:230\u201340.","journal-title":"J Gastroenterol"},{"key":"2454_CR38","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1128\/MCB.20.18.6860-6871.2000","volume":"20","author":"V Taylor","year":"2000","unstructured":"Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM, et al. 5\u2032 phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol. 2000;20:6860\u201371.","journal-title":"Mol Cell Biol"},{"key":"2454_CR39","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1111\/j.1742-4658.2005.04672.x","volume":"272","author":"D Blero","year":"2005","unstructured":"Blero D, Zhang J, Pesesse X, Payrastre B, Dumont JE, Schurmans S, et al. Phosphatidylinositol 3,4,5-trisphosphate modulation in SHIP2-deficient mouse embryonic fibroblasts. FEBS J. 2005;272:2512\u201322.","journal-title":"FEBS J"},{"key":"2454_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2119\/molmed.2011.00178","volume":"18","author":"GM Fuhler","year":"2012","unstructured":"Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park M-Y, et al. Therapeutic potential of SH2 domain-containing inositol-5\u2032-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med. 2012;18:65\u201375.","journal-title":"Mol Med"},{"key":"2454_CR41","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1476-5381.2009.00358.x","volume":"158","author":"A Suwa","year":"2009","unstructured":"Suwa A, Yamamoto T, Sawada A, Minoura K, Hosogai N, Tahara A, et al. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Br J Pharmacol. 2009;158:879\u201387.","journal-title":"Br J Pharmacol"},{"key":"2454_CR42","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.cub.2013.08.044","volume":"23","author":"VP Sharma","year":"2013","unstructured":"Sharma VP, Eddy R, Entenberg D, Kai M, Gertler FB, Condeelis J. Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Curr Biol. 2013;23:2079\u201389.","journal-title":"Curr Biol"},{"key":"2454_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/biology10040266","volume":"10","author":"JA Redondo","year":"2021","unstructured":"Redondo JA, Bibes R, Vercauteren Drubbel A, Dassy B, Bisteau X, Maury E, et al. PER2 circadian oscillation sensitizes esophageal cancer cells to chemotherapy. Biology. 2021;10:266.","journal-title":"Biology"},{"key":"2454_CR44","doi-asserted-by":"publisher","first-page":"eabk0410","DOI":"10.1126\/science.abk0410","volume":"374","author":"F Gulluni","year":"2021","unstructured":"Gulluni F, Prever L, Li H, Krafcikova P, Corrado I, Lo W-T, et al. PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation. Science. 2021;374:eabk0410.","journal-title":"Science"},{"key":"2454_CR45","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2217\/fon.14.53","volume":"10","author":"M Janning","year":"2014","unstructured":"Janning M, Fiedler W. Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncol. 2014;10:1157\u201365.","journal-title":"Future Oncol"},{"key":"2454_CR46","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. Synergyfinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739-43.","journal-title":"Nucleic Acids Res"},{"key":"2454_CR47","first-page":"1","volume":"2014","author":"J Yang","year":"2014","unstructured":"Yang J, Fu M, Ding Y, Weng Y, Fan W, Pu X, et al. High SHIP2 expression indicates poor survival in colorectal cancer. Dis Markers. 2014;2014:1\u20137.","journal-title":"Dis Markers"},{"key":"2454_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080828","volume":"8","author":"M Urashima","year":"2013","unstructured":"Urashima M, Hama T, Suda T, Suzuki Y, Ikegami M, Sakanashi C, et al. Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. PLoS One. 2013;8:e80828.","journal-title":"PLoS One"},{"key":"2454_CR49","doi-asserted-by":"publisher","first-page":"868","DOI":"10.7150\/ijms.16845","volume":"13","author":"X Hu","year":"2016","unstructured":"Hu X, Moon JW, Li S, Xu W, Wang X, Liu Y, et al. Amplification and overexpression of CTTN and CCND1 at chromosome 11q13 in esophagus squamous cell carcinoma (ESCC) of North Eastern Chinese population. Int J Med Sci. 2016;13:868\u201374.","journal-title":"Int J Med Sci"},{"key":"2454_CR50","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2022.04.013","volume":"185","author":"S Battaglioni","year":"2022","unstructured":"Battaglioni S, Benjamin D, W\u00e4lchli M, Maier T, Hall MN. mTOR substrate phosphorylation in growth control. Cell. 2022;185:1814\u201336.","journal-title":"Cell"},{"key":"2454_CR51","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3892\/ol.2017.6526","volume":"14","author":"Z-Z Shan","year":"2017","unstructured":"Shan Z-Z, Chen P-N, Wang F, Wang J, Fan Q-X. Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis. Oncol Lett. 2017;14:2859\u201363.","journal-title":"Oncol Lett"},{"key":"2454_CR52","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women\u2019s Hospital, Broad Institute, Brown University, et al. Integrated genomic characterization of oesophageal carcinoma. Nature et al. 2017;541:169\u201375.","DOI":"10.1038\/nature20805"},{"key":"2454_CR53","first-page":"2185","volume":"6","author":"M Fu","year":"2013","unstructured":"Fu M, Fan W, Pu X, Ni H, Zhang W, Chang F, et al. Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 2013;6:2185\u201391.","journal-title":"Int J Clin Exp Pathol"},{"key":"2454_CR54","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.trecan.2016.05.009","volume":"2","author":"N Thapa","year":"2016","unstructured":"Thapa N, Tan X, Choi S, Lambert PF, Rapraeger AC, Anderson RA. The hidden conundrum of phosphoinositide signaling in cancer. Trends Cancer. 2016;2:378\u201390.","journal-title":"Trends Cancer"},{"key":"2454_CR55","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0006-291X(02)00787-8","volume":"296","author":"S Giuriato","year":"2002","unstructured":"Giuriato S, Blero D, Robaye B, Bruyns C, Payrastre B, Erneux C. SHIP2 overexpression strongly reduces the proliferation rate of K562 erythroleukemia cell line. Biochem Biophys Res Commun. 2002;296:106\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"2454_CR56","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1083\/jcb.201005018","volume":"190","author":"F Nakatsu","year":"2010","unstructured":"Nakatsu F, Perera RM, Lucast L, Zoncu R, Domin J, Gertler FB, et al. The inositol 5-phosphatase SHIP2 regulates endocytic clathrin-coated pit dynamics. J Cell Biol. 2010;190:307\u201315.","journal-title":"J Cell Biol"},{"key":"2454_CR57","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1242\/jcs.179663","volume":"129","author":"W Elong Edimo","year":"2016","unstructured":"Elong Edimo W, Ghosh S, Derua R, Janssens V, Waelkens E, Vanderwinden J-M, et al. SHIP2 controls plasma membrane PI(4,5)P2 thereby participating in the control of cell migration in 1321 N1 glioblastoma cells. J Cell Sci. 2016;129:1101\u201314.","journal-title":"J Cell Sci"},{"key":"2454_CR58","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nature14067","volume":"517","author":"E Boucrot","year":"2015","unstructured":"Boucrot E, Ferreira APA, Almeida-Souza L, Debard S, Vallis Y, Howard G, et al. Endophilin marks and controls a clathrin-independent endocytic pathway. Nature. 2015;517:460\u20135.","journal-title":"Nature"},{"key":"2454_CR59","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cell.2019.09.008","volume":"179","author":"A Lundby","year":"2019","unstructured":"Lundby A, Franciosa G, Emdal KB, Refsgaard JC, Gnosa SP, Bekker-Jensen DB, et al. Oncogenic mutations rewire signaling pathways by switching protein recruitment to phosphotyrosine sites. Cell. 2019;179:543\u2013e56026.","journal-title":"Cell"},{"key":"2454_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2019.100660","volume":"75","author":"AR Ramos","year":"2020","unstructured":"Ramos AR, Ghosh S, Suhel T, Chevalier C, Obeng EO, Fafilek B, et al. Phosphoinositide 5-phosphatases SKIP and SHIP2 in ruffles, the endoplasmic reticulum and the nucleus: an update. Adv Biol Regul. 2020;75:100660.","journal-title":"Adv Biol Regul"},{"key":"2454_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","volume":"18","author":"J Yang","year":"2019","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18:26.","journal-title":"Mol Cancer"},{"key":"2454_CR62","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1038\/ncomms5620","volume":"5","author":"C Lin","year":"2014","unstructured":"Lin C, Liu A, Zhu J, Zhang X, Wu G, Ren P, et al. Mir-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nat Commun. 2014;5:4620.","journal-title":"Nat Commun"},{"key":"2454_CR63","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.canlet.2019.07.004","volume":"461","author":"JJ Caumanns","year":"2019","unstructured":"Caumanns JJ, van Wijngaarden A, Kol A, Meersma GJ, Jalving M, Bernards R, et al. Low-dose triple drug combination targeting the PI3K\/AKT\/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. Cancer Lett. 2019;461:102\u201311.","journal-title":"Cancer Lett"},{"key":"2454_CR64","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1038\/s41467-020-16952-9","volume":"11","author":"JM Fernandes Neto","year":"2020","unstructured":"Fernandes Neto JM, Nadal E, Bosdriesz E, Ooft SN, Farre L, McLean C, et al. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nat Commun. 2020;11:3157.","journal-title":"Nat Commun"},{"key":"2454_CR65","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8:38022\u201343.","journal-title":"Oncotarget"},{"key":"2454_CR66","doi-asserted-by":"publisher","first-page":"78452","DOI":"10.18632\/oncotarget.19632","volume":"8","author":"Y Adachi","year":"2017","unstructured":"Adachi Y, Ishikawa Y, Kiyoi H. Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia. Oncotarget. 2017;8:78452\u201365.","journal-title":"Oncotarget"},{"key":"2454_CR67","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/ncomms2879","volume":"4","author":"K Kasahara","year":"2013","unstructured":"Kasahara K, Goto H, Izawa I, Kiyono T, Watanabe N, Elowe S, et al. PI 3-kinase-dependent phosphorylation of Plk1\u2013Ser99 promotes association with 14-3-3\u03b3 and is required for metaphase\u2013anaphase transition. Nat Commun. 2013;4:1882.","journal-title":"Nat Commun"},{"key":"2454_CR68","first-page":"376","volume":"28","author":"D Chen","year":"2023","unstructured":"Chen D, Lei C, Liu W, Shao M, Sun M, Guo J, et al. Reduction-responsive nucleic acid nanocarrier-mediated miR-22 inhibition of PI3K\/AKT pathway for the treatment of patient-derived tumor xenograft osteosarcoma. Bioact Mater. 2023;28:376\u201385.","journal-title":"Bioact Mater"},{"key":"2454_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040890","volume":"13","author":"C Pedicone","year":"2021","unstructured":"Pedicone C, Meyer ST, Chisholm JD, Kerr WG. Targeting SHIP1 and SHIP2 in cancer. Cancers (Basel). 2021;13:13:890.","journal-title":"Cancers (Basel)"},{"key":"2454_CR70","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gad.12.11.1610","volume":"12","author":"CD Helgason","year":"1998","unstructured":"Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappel SM, et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 1998;12:1610\u201320.","journal-title":"Genes Dev"},{"key":"2454_CR71","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1089\/scd.2014.0501","volume":"24","author":"S Iyer","year":"2015","unstructured":"Iyer S, Brooks R, Gumbleton M, Kerr WG. SHIP1-expressing mesenchymal stem cells regulate hematopoietic stem cell homeostasis and lineage commitment during aging. Stem Cells Dev. 2015;24:1073\u201381.","journal-title":"Stem Cells Dev"},{"key":"2454_CR72","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER, Kalocsay M, et al. Quantitative proteomics of the cancer cell line encyclopedia. Cell. 2020;180:387\u2013e40216.","journal-title":"Cell"},{"key":"2454_CR73","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-013-1111-z","volume":"125","author":"K Ando","year":"2013","unstructured":"Ando K, Brion J-P, Stygelbout V, Suain V, Authelet M, Dedecker R, et al. Clathrin adaptor CALM\/PICALM is associated with neurofibrillary tangles and is cleaved in alzheimer\u2019s brains. Acta Neuropathol. 2013;125:861\u201378.","journal-title":"Acta Neuropathol"},{"key":"2454_CR74","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3233\/JAD-201046","volume":"79","author":"H Kumon","year":"2021","unstructured":"Kumon H, Yoshino Y, Funahashi Y, Mori H, Ueno M, Ozaki Y, et al. PICALM mRNA expression in the blood of patients with neurodegenerative diseases and geriatric depression. J Alzheimers Dis. 2021;79:1055\u201362.","journal-title":"J Alzheimers Dis"},{"key":"2454_CR75","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1042\/bj3420697","volume":"342","author":"E Muraille","year":"1999","unstructured":"Muraille E, Pesesse X, Kuntz C, Erneux C. Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signalling of B-cells. Biochem J. 1999;342:697\u2013705.","journal-title":"Biochem J"},{"key":"2454_CR76","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTseq\u2013a python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166\u20139.","journal-title":"Bioinformatics"},{"key":"2454_CR77","unstructured":"Powell D. drpowell\/degust 4.1.1 [Internet]. Zenodo; 2019 [cited 2021 Mar 23]. Available from: https:\/\/zenodo.org\/record\/3501067"},{"key":"2454_CR78","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12859-018-2486-6","volume":"19","author":"SX Ge","year":"2018","unstructured":"Ge SX, Son EW, Yao R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics. 2018;19:534.","journal-title":"BMC Bioinformatics"},{"key":"2454_CR79","doi-asserted-by":"publisher","unstructured":"Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis [Internet]. Bioinformatics; 2016 Jun. Available from: http:\/\/biorxiv.org\/lookup\/doi\/https:\/\/doi.org\/10.1101\/060012","DOI":"10.1101\/060012"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02454-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:03:02Z","timestamp":1762290182000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02454-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2454"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02454-z","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the ULB Ethical Committee (protocols 668\u00a0N and 821\u00a0N). No human participants were involved, and no human samples were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.B. is the inventor on a pending patent related to SHIP2\/PLK1 combined inhibition in esophageal cancer. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}